Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitor Combined With Endocrine Therapy

NCT05860465 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT05860465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05860465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitor Combined With Endocrine Therapy
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 8, 2023
Completion date
December 30, 2026
Enrollment
254 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic breast cancer